Compare Stocks → Move Your Money Before May 1 (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APRENASDAQ:BPTSNASDAQ:NEPTNASDAQ:OTICNASDAQ:REPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$5.20-2.8%$6.40$2.78▼$8.85$28.24M1.0329,016 shs4,833 shsBPTSBiophytis$8.22-15.3%$16.10$8.05▼$168.80$2.88M1.0523,135 shs18,549 shsNEPTNeptune Wellness Solutions$0.39$0.19▼$28.00$906K2.19462,687 shs2.25 million shsOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/AREPHRecro Pharma$1.73$1.38▼$3.79$117.93M1.08126,298 shs141,800 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics+5.52%-8.39%-9.63%+2.88%+40.05%BPTSBiophytis-15.26%-37.73%-48.63%-58.90%-93.77%NEPTNeptune Wellness Solutions0.00%0.00%0.00%-55.36%-99.22%OTICOtonomy0.00%0.00%0.00%0.00%0.00%REPHRecro Pharma0.00%0.00%0.00%0.00%0.00%These AI trades triggered this morning (545% return) (Ad)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free CopyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPREAprea Therapeutics2.8143 of 5 stars3.55.00.00.00.03.30.6BPTSBiophytis2.3239 of 5 stars3.55.00.00.01.90.00.6NEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/AN/AN/AN/AREPHRecro PharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics3.00Buy$15.50198.08% UpsideBPTSBiophytis3.00Buy$600.007,199.27% UpsideNEPTNeptune Wellness SolutionsN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AREPHRecro PharmaN/AN/AN/AN/ACurrent Analyst RatingsLatest NEPT, REPH, BPTS, OTIC, and APRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$9.00 ➝ $11.003/26/2024APREAprea TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$580K48.68N/AN/A$4.54 per share1.15BPTSBiophytisN/AN/AN/AN/A($17.29) per shareN/ANEPTNeptune Wellness Solutions$52.62M0.00N/AN/A($91.90) per share0.00OTICOtonomy$130K4.48N/AN/A$0.97 per share0.01REPHRecro Pharma$75.36M0.00N/AN/A$0.90 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$14.29M-$3.99N/AN/AN/AN/A-65.58%-52.37%5/20/2024 (Estimated)BPTSBiophytis-$18.43MN/A0.00N/AN/AN/AN/AN/AN/ANEPTNeptune Wellness Solutions-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%7/15/2024 (Estimated)OTICOtonomy-$51.18M-$0.77N/A∞N/AN/A-137.86%-68.50%N/AREPHRecro Pharma-$11.37M-$0.31N/AN/AN/A-15.15%-56.66%-11.14%N/ALatest NEPT, REPH, BPTS, OTIC, and APRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023APREAprea Therapeutics-$0.56-$0.92-$0.36-$0.92$0.33 million$0.01 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/ABPTSBiophytisN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/AREPHRecro PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A5.135.13BPTSBiophytisN/A0.720.72NEPTNeptune Wellness SolutionsN/A0.230.10OTICOtonomyN/A1.741.74REPHRecro Pharma2.273.242.74OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%BPTSBiophytis0.05%NEPTNeptune Wellness Solutions14.44%OTICOtonomy41.23%REPHRecro Pharma62.34%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics20.90%BPTSBiophytis3.70%NEPTNeptune Wellness Solutions5.10%OTICOtonomy1.09%REPHRecro Pharma14.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics75.43 million4.30 millionNo DataBPTSBiophytis26350,000338,000Not OptionableNEPTNeptune Wellness Solutions584.53 million4.30 millionNot OptionableOTICOtonomy5168.53 million67.78 millionOptionableREPHRecro Pharma18556.42 million48.41 millionOptionableNEPT, REPH, BPTS, OTIC, and APRE HeadlinesSourceHeadlineDorf Ketal's Indian unit acquires veterinary pharma brandvccircle.com - April 10 at 10:57 PMFuji Pharma Co. Ltd.wsj.com - January 30 at 3:34 PMAurobindo Pharma Q2 results: Net profit jumps 85% to Rs 757 croremoneycontrol.com - November 22 at 10:47 PMRetaining the human element of AI within pharma and healthcarepharmaphorum.com - November 21 at 10:06 AMHere's what Wall Street expects from Recro Pharma's earnings reportmarkets.businessinsider.com - November 7 at 12:00 PMUS supreme court halts Purdue Pharma deal that shields Sacklers from lawsuitstheguardian.com - August 16 at 1:59 AMMankind Pharma share pricelivemint.com - August 9 at 12:30 PMWhat Wall Street expects from Recro Pharma's earningsmarkets.businessinsider.com - August 9 at 7:25 AMMankind Pharma Ltd (MNKI)investing.com - August 3 at 9:00 AMEversana and Amazon plan generative AI push in pharmapharmaphorum.com - July 30 at 11:21 PMAurobindo Pharma Ltd.ndtv.com - July 25 at 12:39 AMBaudax Bio acquires Maryland biotechnology firm TeraImmune; stock jumpsbizjournals.com - June 30 at 12:44 PMPharma reform: Patients can’t afford to wait. Act now.politico.eu - June 13 at 3:41 PMSun Pharma reports "information security incident"; isolates impacted IT assetshealth.economictimes.indiatimes.com - March 9 at 7:26 AMWatch: Woody Harrelson Torches Big Pharma During Hilarious Opening Monologue on SNLijr.com - March 2 at 12:30 AMAurobindo Pharma shares gain even as Q3 profit sinks; board declares 300% dividendmoneycontrol.com - February 17 at 8:43 PMPaytm, Adani Enterprises, HUL, Sun Pharma, Lupin, Cummins, GAIL, Macrotech Developers stocks in focusfinancialexpress.com - December 20 at 8:48 AMPomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Recro Pharma, Inc. Common Stock – SCTLbenzinga.com - June 24 at 9:08 AMSocietal CDMO Increuters.com - April 20 at 9:24 AMRecro Pharma, Inc.: Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformationfinanznachrichten.de - March 22 at 10:51 PMRecro Pharma Rebrands to Societal CDMO Inc.contractpharma.com - March 22 at 5:51 PMIs Recro Pharma (REPH) a Worthy Investment?finance.yahoo.com - March 22 at 8:32 AMRecap: Recro Pharma Q4 Earningsbenzinga.com - March 1 at 11:55 PMRecro Pharma Progresses Addition of Fill/Finish, Lyophilization Capabilitiescontractpharma.com - February 23 at 9:51 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioCanoo, Inc. Bites the Dust: Mullen Automotive Is a Better BetApril 2, 2024 9:15 AMView Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet3 Computer Vision Stocks for Long-Term Gains From AIApril 16, 2024 6:08 AMView 3 Computer Vision Stocks for Long-Term Gains From AICan Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?April 10, 2024 7:55 AMView Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?Intuitive Surgical Leads the Robotic Surgery MovementApril 22, 2024 6:10 AMView Intuitive Surgical Leads the Robotic Surgery MovementAll Headlines Company DescriptionsAprea TherapeuticsNASDAQ:APREAprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.BiophytisNASDAQ:BPTSBiophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.Neptune Wellness SolutionsNASDAQ:NEPTNeptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada. OtonomyNASDAQ:OTICOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.Recro PharmaNASDAQ:REPHRecro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.